Sector
PharmaceuticalsOpen
₹7.52Prev. Close
₹7.52Turnover(Lac.)
₹0.23Day's High
₹7.6Day's Low
₹7.5252 Week's High
₹13.4752 Week's Low
₹6.7Book Value
₹0.81Face Value
₹2Mkt Cap (₹ Cr.)
7.79P/E
250.67EPS
0.03Divi. Yield
04 Dec 2023
12:00 AM
EGM
31 Jul 2024
12:00 AM
AGM
Announcement Date: 31 Jul, 2024
15 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 2.05 | 2.05 | 10.25 | 10.25 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -1.25 | -1.3 | -9.46 | -8.95 |
Net Worth | 0.8 | 0.75 | 0.78 | 1.3 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1.03 | 1.94 | 1.03 | 1.01 |
yoy growth (%) | -46.89 | 88.46 | 1.84 | -19.64 |
Raw materials | -0.68 | -1.3 | -0.56 | -0.72 |
As % of sales | 65.93 | 66.92 | 55.04 | 71.82 |
Employee costs | -0.24 | -0.25 | -0.22 | -0.26 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -0.95 | 0.11 | -2.27 | -0.48 |
Depreciation | 0 | -0.01 | 0 | -0.01 |
Tax paid | 0.01 | -0.03 | 0 | 0 |
Working capital | -0.87 | 1.25 | 0.09 | -0.13 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -46.89 | 88.46 | 1.84 | -19.64 |
Op profit growth | -791.35 | -105.78 | 404.59 | 278.8 |
EBIT growth | -860.9 | -105.49 | 376.04 | 255.53 |
Net profit growth | -1,262.13 | -103.55 | 362.89 | -76.45 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
J.V.R. Mohan Raju
Non Executive Director
J Uma
Independent Director
Reji Abraham
Director & CFO
Jaison George
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Hindustan Bio Sciences Ltd
Summary
Hindustan Bio Science Ltd (Formerly known Hindustan Softel Ltd) was incorporated as Public Limited Company on December 16, 1991. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified operations in pharmaceutical and biotechnology sectors. The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.Previously, it was engaged in cement manufacturing and due to sluggish in the industry the company diversified its business into Bio Technology & Pharmaceuticals activities and the name of the Company was changed from Garuda Cements to Hindustan Bio-Sciences Ltd. In 2001, it diversified into software field and subsequently changed its name to Hindustan Softel Limited which presently got changed into Hindustan Bio Sciences Ltd.The Company acquired the shares of Venkar Chemicals Ltd in 2004 and consequently upon acquisition, it became Wholly owned subsidiary of the Company with effect from 19.08.2004.During 2006-07, Company got approval from Drugs Controller General of India (DCGI) and started marketing the nephrology product Recombinant Human Erythropoietin with the brand name EPOVIN from June, 2007.The Company to its credit has world class manufacturing facilities for dry and liquid injectables, liquid/dry syrups, Eye/Ear/Nasal drops, pre-filled syringes and non sterile/sterile ointments, tablets and capsules
Read More
What is the Hindustan Bio Sciences Ltd share price today?
The Hindustan Bio Sciences Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹7.6 today.
What is the Market Cap of Hindustan Bio Sciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hindustan Bio Sciences Ltd is ₹7.79 Cr. as of 09 May ‘25
What is the PE and PB ratio of Hindustan Bio Sciences Ltd?
The PE and PB ratios of Hindustan Bio Sciences Ltd is 250.67 and 9.22 as of 09 May ‘25
What is the 52 Week High and Low of Hindustan Bio Sciences Ltd?
The 52-week high/low is the highest and lowest price at which a Hindustan Bio Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Hindustan Bio Sciences Ltd is ₹6.7 and ₹13.47 as of 09 May ‘25
What is the CAGR of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd's CAGR for 5 Years at 44.59%, 3 Years at 24.68%, 1 Year at -12.46%, 6 Month at -28.04%, 3 Month at -13.56% and 1 Month at -13.06%.
What is the shareholding pattern of Hindustan Bio Sciences Ltd?
The shareholding pattern of Hindustan Bio Sciences Ltd is as follows:
Promoters - 12.19 %
Institutions - 0.00 %
Public - 87.81 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
